Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:567486.
doi: 10.1155/2009/567486. Epub 2009 May 6.

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Amir Harandi  1 , Aisha S Zaidi, Abigail M Stocker, Damian A Laber
Affiliations

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Amir Harandi et al. J Oncol. 2009.

Abstract

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. The New England Journal of Medicine. 1980;303(15):878–880. - PubMed
    1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology. 1995;19(3):183–232. - PubMed
    1. Citri A, Yarden Y. EGF-ERBB randomize: towards the systems level. Nature Reviews Molecular Cell Biology. 2006;7(7):505–516. - PubMed
    1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. 2005;5(5):341–354. - PubMed
    1. Khazaeli MB, LoBuglio AF, Falcey JW, et al. Low immunogenicity of a chimeric monoclonal antibody (MoAB), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; May 2000; New Orleans, La, USA. abstract no. 207a.